AGP Executive Report

Cancer Vaccines: A personalized mRNA vaccine paired with Merck’s Keytruda cut melanoma recurrence or death risk by 42% versus Keytruda alone, fueling efforts to test the approach in other cancers. Weight-Loss Drugs: Lilly’s retatrutide outperformed Ozempic in a head-to-head type 2 diabetes trial for weight loss and blood sugar control. Stroke Response: On World Stroke Day, clinicians urged people to use the FAST signs—face drooping, arm weakness, speech trouble—to recognize a stroke and call emergency services immediately. Hospital Expansion: Fortis Healthcare completed its roughly Rs 277 crore acquisition of Bengaluru’s 110-bed Suguna Hospital, with scope to expand the site to 150 beds. Medicine Access: A report found uneven uptake of some new medicines across Scotland’s health boards, particularly GLP-1 drugs, pointing to possible avoidable barriers for patients. Drug Manufacturing: Ghana launched a policy to raise the share of locally made medicines from about 30% to 60% and reduce reliance on imports.

Imaging Expansion: RadNet agreed to acquire teleradiology provider Onrad for $350 million upfront, plus shares and potential milestones, adding a new business as hospitals seek help with radiologist staffing. Cancer R&D: Astellas will pay Audax Bio $285 million upfront, with the deal potentially reaching $1.34 billion, for an early-stage immunotherapy designed to concentrate immune activity in tumors. A Phase 1 trial is planned for 2027. Medicaid Coverage: New work requirements starting in January could put one in five Medicaid expansion adults at risk of losing coverage. Many enrollees are unaware of the rules, and inconsistent work hours could complicate compliance. Drug Prices: India’s Supreme Court challenged steep hospital markups and the government’s reluctance to expand price controls, saying industry growth cannot outweigh patients’ access to medicines. Diabetes Trial: Lilly said its triple-hormone drug outperformed Ozempic in a diabetes study, intensifying competition in the treatment market. GSK Results: Vaccine sales fell 2% in the third quarter, led by declines for Shingrix and Arexvy, while overall revenue rose 5% on stronger specialty medicine and HIV sales.

Maternal Health: A study of more than one million births found that pregnancy weight gain above recommended levels was associated with more severe complications across all pre-pregnancy BMI groups; the observational findings do not prove cause and effect. Climate and Health: A Lancet report estimates heat caused three million deaths worldwide from 2016 to 2023 and calls for climate change to be declared a global health emergency. Brain TB: Researchers say lingering MRI abnormalities may keep some patients on treatment after recovery, despite low relapse rates—raising concerns about unnecessary medication and costs. Medicine Prices: India’s Supreme Court challenged large gaps between drug costs and listed prices, questioning whether essential medicines are being treated as commerce. Fertility Industry: Ferring agreed to acquire Gameto for up to $1.4 billion, adding an IVF technology that aims to shorten treatment cycles; U.S. Phase 3 testing is underway. Healthcare AI: A study found AI-generated care plans cost three times as much as physicians’ plans, largely because they recommended more tests.

Medicine Costs: India’s Supreme Court challenged large gaps between medicine prices and retailer costs, criticizing the government’s oversight and calling the pricing authority “totally defunct.” Vaccination: Nepal will receive Rs 8.59 billion in GAVI support through 2030 to sustain its national immunization program; a disputed repayment was also waived. Cancer Care: In a phase 3 trial, sacituzumab tirumotecan improved survival over chemotherapy for previously treated advanced endometrial cancer, cutting the risk of death by 32%. The FDA also approved talazoparib with enzalutamide for certain men with advanced prostate cancer. Drug Safety: Bristol Myers Squibb disclosed a patient death from septic pneumonia during a CAR-T trial for multiple sclerosis; the company said it cannot determine whether treatment caused the death. Obesity Treatment: A phase 3 trial found tradipitant reduced vomiting after semaglutide, a side effect that can lead patients to stop GLP-1 treatment; Vanda plans to seek FDA approval for the use.

Cancer Advances: FDA expanded talazoparib plus enzalutamide for HRR-mutated hormone-sensitive prostate cancer, while sacituzumab tirumotecan cut the risk of death by 32% in advanced endometrial cancer. The FDA also granted breakthrough status to enzomenib for a high-risk leukemia subtype. Drug Industry: South Korea’s bio-health exports rose 19.4% to a record $24.8 billion in the first nine months, powered by pharmaceuticals and biologics. Health IT: A new federal rule removes or revises health IT certification requirements, including narrowing rules for clinical decision-support tools, while retaining privacy and security criteria. Patient Safety: Low health literacy can make prescriptions and care instructions harder to follow, with consequences for health and healthcare costs.

Cancer Research: Phase 3 data presented at ESMO show Moderna and Merck’s personalized melanoma vaccine plus pembrolizumab cut recurrence risk by 42% versus pembrolizumab alone; 24.6-month recurrence-free survival was 82.2% versus 70%. AI Drug Development: Bristol Myers Squibb is backing Pathos AI’s work with Tempus to build neurological-disease data and AI tools for drug research, with BMS leading Pathos’s Series E financing. Ebola Response: Bundibugyo Ebola cases in Kenya and Nigeria are prompting calls for coordinated regional surveillance as the DRC outbreak continues; there is no approved vaccine or drug for this strain. Medical Devices: Edwards Lifesciences won FDA approval for a tricuspid valve repair device. Care Delivery: Pharmacists say their medication expertise can help fill gaps in care, including connecting uninsured patients with assistance programs.

Cancer Advances: ESMO 2026 results point to new treatment options: adding darolutamide to hormone therapy and radiation cut the risk of metastasis or death in very high-risk localized prostate cancer, while tarlatamab plus durvalumab extended survival in small-cell lung cancer. Ebola Response: Nigeria has isolated 53 contacts linked to an imported case in Abuja and approved weekly payments to help them meet expenses during isolation; Lagos says it is strengthening airport screening and surveillance. Early Detection: Indian experts say AI could help flag possible tuberculosis and lung cancer on scans, prioritizing patients for follow-up. Global Health: WHO chief Tedros praised South Korea’s new vaccine-manufacturing training hub, designed to train about 2,000 people annually and build production capacity in lower-income countries. Care Costs: Rising medical bills are weighing on families, with a recent poll finding about half of US voters call healthcare costs a major problem.

Ebola Watch: The DRC outbreak has reached 9,735 cases, while infections have also been reported in Kenya, Uganda, Nigeria and France. Kenya reports nine cases and one death; the CDC says risk to the U.S. public is low. Nigerian pharmacists are urging a “Pharmacy First” plan to help spot cases early. Vaccine Update: Pfizer says its experimental 25-valent pneumococcal vaccine produced stronger antibody responses to serotype 3 in infants than Prevnar 20; reported safety events were balanced, but detailed results are not yet public. Cancer Care: Longer follow-up of Regeneron’s Libtayo trial found a growing survival benefit for people with high-risk cutaneous squamous cell carcinoma after surgery and radiation. Bladder Cancer: In the VOLGA study, durvalumab plus enfortumab vedotin cut the risk of death by 42% in patients with muscle-invasive disease who could not take platinum chemotherapy; adding tremelimumab offered no added benefit. Healthcare Costs: Workers’ average contribution to family job-based coverage rose 9% to $7,471 this year, while average premiums reached $28,303.

Health Technology: Siemens plans to send a healthcare delegation to Pakistan to pursue agreements on training and technology; the talks signal possible cooperation, not completed projects. Cancer Research: New ESMO data show durvalumab plus enfortumab vedotin improved event-free and overall survival in muscle-invasive bladder cancer patients unable or unwilling to receive cisplatin. Another study found apalutamide plus hormone therapy improved event-free survival in high-risk prostate cancer. Coverage Costs: Employer health plans are getting pricier: workers’ average annual contribution for family coverage rose 9% to $7,471, while average premiums reached $28,303, according to KFF. Drug Supply: Pakistan faces a shortage of imported rapid-acting insulin after a factory upgrade halted supplies; alternatives cost at least 20% more, while delayed price approvals have also disrupted access to essential medicines. Industry Growth: Ghana’s presidential candidate Mahamudu Bawumia discussed expanding local drug production and streamlining regulation with the Pharmaceutical Society of Ghana, pitching the country as a regional manufacturing hub.

Industrial Safety: Telangana’s human rights commission is seeking a report after a suspected chloroform leak at a pharmaceutical plant killed two workers and hospitalized six; three remain under treatment. Measles: U.S. cases have reached 4,588 this year, more than double 2025’s total, with Pennsylvania reporting 1,338 cases. About 96% nationally involve people who are unvaccinated or whose status is unknown. Coverage and Care: Humana and UnitedHealthcare are ending Medicare Advantage plans for about 1 million seniors next year. Separately, a Commonwealth Fund survey found 11.2% of working-age Americans were uninsured in 2026, while half delayed or skipped care because of cost. Clinical Research: AstraZeneca plans to invest $50 million in about 30 Abu Dhabi trials focused on cardiovascular, kidney and metabolic diseases. At ESMO, BMS’s antibody-drug conjugate cut progression or death risk by 59% versus chemotherapy in advanced breast cancer; GSK reported a 62% response rate for its ovarian cancer candidate, with severe treatment-related side effects in 71% of patients. Devices and Workforce: Edwards won FDA approval to use its Pascal system for tricuspid valve repair. CMS also launched a $275 million initiative offering eligible nursing-home nurses up to $40,000 in loan repayment or a $10,000 stipend.

Cancer Advances: New melanoma-vaccine results from Moderna and Merck showed 42% fewer recurrences and 38% less distant spread after surgery, drawing praise from oncologists even as the companies’ shares fell. ESMO also featured promising pancreatic-cancer data for daraxonrasib and activity for pembrolizumab plus chemotherapy in neuroendocrine prostate cancer. Flu Watch: Flu is rising early in parts of North America, and a CDC tool now tracks local trends in flu, COVID-19 and RSV. Researchers say a flu mutation first detected in Japan may be contributing to the early surge, though its role remains uncertain. Point-of-Care Screening: IIT Bombay researchers developed a low-cost blood-smear device designed to screen for anaemia and sickle cell disease using a drop of blood. Treatment Updates: The FDA approved a subcutaneous induction option for risankizumab in Crohn’s disease; trial results also showed fewer relapses with remibrutinib than teriflunomide in relapsing MS. Access and Costs: Five major companies pledged faster electronic prior authorizations, while a proposed US expansion of investment restrictions to biotechnology could affect cross-border research and drug development.

Drug Supply: Dr Reddy’s has introduced two more generic semaglutide brands in India after an impurity issue halted supplies of its original Obeda injection. US Manufacturing: Eli Lilly broke ground on a $6.5 billion Houston plant focused on oral GLP-1 medicines, including its obesity treatment orforglipron. Cancer Care: NICE will fund five AI tools to help NHS radiologists spot prostate cancer on MRI scans while further real-world data are collected. Patient Safety: India has ordered hospitals to stop reusing single-use medical devices, citing infection risks and improper charges to patients. Cancer Research: New melanoma trial analyses found lower recurrence and metastasis risks with Merck and Moderna’s personalized mRNA vaccine combined with pembrolizumab. Biotech Policy: A proposed US expansion of investment restrictions to Chinese biotech could affect deals and access to drug-development technologies.

Cancer Advances: Merck and Moderna reported that adding their personalized mRNA therapy to Keytruda cut recurrence risk by 42% in resected melanoma; results will be presented at ESMO. The FDA also granted Keytruda traditional approval for certain TMB-high solid tumors. New Drug Approvals: The FDA approved GSK and Ionis’ Hibsago, an antisense treatment for chronic hepatitis B, and granted AstraZeneca’s Ultomiris accelerated approval for adults with IgA nephropathy. Biotech Policy: The U.S. proposed restrictions on American investment in Chinese biotech, potentially complicating drugmakers’ growing partnerships with Chinese innovators. Data Security: Quest Diagnostics reported unauthorized access to its lab-services platform; some patient records may have been accessed, but the number is not yet known. Care Costs: Employer family health premiums averaged $28,303 in 2026, up 5% from last year.

Healthcare Data: Synology says demand for its storage systems from Malaysian healthcare and government organizations is driving strong sales growth. The company urged providers to test backups against ransomware, accidental deletion and insider threats. Clinical Trials: FDA and industry experts explored selective safety-data collection in trial scenarios, aiming to reduce research burdens while maintaining patient safeguards. AI in Drug Development: Boehringer Ingelheim and Microsoft will study digital patient models and trial simulations that could make studies more efficient and help therapies reach patients sooner. Rural Care: India’s CureBay raised ₹100 crore to expand its technology-enabled rural clinics and develop AI tools for screening and clinical decisions. Infectious Disease: France reported the first known human Shamonda virus case, ending in the death of a severely immunocompromised patient; authorities say there is no known risk to the public. Remote Monitoring: A proposed Medicare rule could restrict reimbursement when outside technology companies support remote patient monitoring, potentially limiting access for rural patients with chronic conditions.

Hepatitis B: The FDA approved GSK’s Hibsago (bepirovirsen), the first antisense treatment for chronic hepatitis B. In trials, 19% of patients achieved a functional cure after six months, compared with none on placebo. Women’s Health: An observational study linked fezolinetant to improved mild depression and anxiety symptoms in women with menopausal hot flashes. It is not approved to treat either condition, and researchers say it’s unclear whether mood benefits are direct or tied to hot-flash relief. Outbreak Watch: Nigeria confirmed an Ebola case, prompting increased surveillance and contact tracing, with WHO support. Drug Access: A new report says median net launch prices for new medicines rose 35% from 2022 to 2025, reaching $257,000; it also found many prescriptions go unfilled after coverage rejections. Diabetes Prevention: International guidance backs screening all children for early-stage type 1 diabetes, since most new cases occur in children with no family history.

Treatment Advances: Rusfertide improved hematocrit control and reduced phlebotomy in polycythemia vera, with reported gains in fatigue and symptom burden. In a phase 2 C. difficile trial, LMN-201 plus antibiotics achieved an 83.3% global cure rate versus 36.4% with placebo; recurrence was 9.1% versus 55.6%. Precision Medicine: Prime editing repaired a GATA2 mutation in patient-derived stem cells in preclinical research. An Indian AI-based breast cancer test aims to help identify early-stage patients who may not benefit from chemotherapy. AI in Care: Cancer specialists say AI can help identify people eligible for lung screening, but human counseling and representative training data remain essential. Public Health: Nigeria confirmed an Ebola case, with health authorities tracing 44 contacts as an outbreak spreads in the region. Industry & Access: Median net launch prices for new drugs rose 35% from 2022 to 2025, reaching $257,000, keeping affordability in focus. Medtech executives also expect more small acquisitions and portfolio cuts.